<SEC-DOCUMENT>0001144204-15-051858.txt : 20150826
<SEC-HEADER>0001144204-15-051858.hdr.sgml : 20150826
<ACCEPTANCE-DATETIME>20150826090013
ACCESSION NUMBER:		0001144204-15-051858
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150826
FILED AS OF DATE:		20150826
DATE AS OF CHANGE:		20150826

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		151074698

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v419042_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 12pt"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">For the month of August, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">Commission File Number: <B>000-36000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 12pt"><B><U>XTL
Biopharmaceuticals Ltd.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">(Translation of registrant&rsquo;s name
into English)</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>5 HaCharoshet St.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>Raanana 4365603</B><BR>
<B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Israel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">(Address of principal
executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No. 333-148085,
File No. 333-148754 and File No. 333-154795) and Form F-3 (File No. 194338).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 77px; width: 255px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>XTL
ANNNOUNCES PUBLICATION OF </B></FONT><B>RESULTS OF PHASE 2 STUDY ON hCDR1 (Edratide) IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
(SLE) IN <FONT STYLE="text-transform: uppercase">LUPUS SCIENCE &amp; MEDICINE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>RAANANA,
Israel</B></FONT><B> - (August 26, 2015) &ndash; XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) </B>(&ldquo;XTL&rdquo;
or the &ldquo;Company&rdquo;), announced today that previously reported results of a Phase 2b study on the safety and efficacy of its
lead drug candidate, hCDR1 (Edratide) for the treatment of SLE (lupus) were published in the Lupus Science &amp; Medicine Journal.
See link for full article (<FONT STYLE="color: Blue"><U>http://lupus.bmj.com/content/2/1/e000104.full</U></FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The article, authored by leading rheumatologists,
Dr. Murray Urowitz, Dr. David Isenberg and Dr. Dan Wallace, reported the results of a study conducted by Teva Pharmaceuticals in
which Edratide demonstrated efficacy in one and possibly more clinically meaningful endpoints. According to the article, dose ranging
studies demonstrated that the 0.5mg dose administered weekly as a subcutaneous injection was the most effective dose and that the
drug showed no safety signals in the 26 week study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further the article stated that the study
(PRELUDE) showed that Edratide was safe and well tolerated and while the primary endpoints based solely on SLEDAI-2K and AMS were
not met, the secondary predefined endpoint, BILAG, was met for the 0.5 mg Edratide arm in the intention to treat (ITT) cohort (N=316)
(OR=2.09, p=0.03) with trends in the 1.0 and 2.5 mg doses. The article also stated that there was a positive trend in the Composite
SLE Responder Index of the ITT cohort and post hoc analysis showed that the BILAG secondary endpoint was also met for the 0.5 mg
Edratide for a number of subgroup dose levels, including low or no steroids, seropositivity and patients with 2 grade BILAG improvement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The article concluded that the favorable
safety profile and encouraging clinically significant effects noted in some of the endpoints support the need for additional longer
term Edratide studies that incorporate recent advances in the understanding and treatment of SLE, including steroid treatment algorithms,
and using a composite primary endpoint which is likely to include BILAG.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Josh Levine, Chief Executive Officer of
XTL, commented, &ldquo;The encouraging data published in a peer-reviewed article in Lupus Science &amp; Medicine regarding Edratide,
our lead drug candidate for the treatment of SLE, further strengthens XTL&rsquo;s resolve to bring this drug candidate to market
as soon as possible. With the recent announcements of drugs being developed for the treatment of lupus by UCB and Eli Lilly failing
to reach their primary endpoints in Phase 3 trials, there remains a significant unmet medical need in SLE.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We believe that there is a substantial
opportunity for our lead drug candidate, hCDR1 (Edratide). We look forward to continuing the development of Edratide in advanced
clinical trials and providing a measure of hope to patients suffering from this disease and the clinicians who treat them. We will
continue to share our progress with you in the coming months.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">XTL Biopharmaceuticals Ltd.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; font: 10pt Times New Roman, Times, Serif; text-align: center">5 Hacharoshet Street, Raanana, 43656, Israel</TD>
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: right">Page 1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tel: +972 9 955 7080; email: <FONT STYLE="color: Blue"><U>ir@xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About XTL Biopharmaceuticals Ltd.
(&ldquo;XTL&quot;)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL Biopharmaceuticals Ltd., a biopharmaceutical
company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet
clinical needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL is a public company, traded on the
Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices:
Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>For further information, please
contact:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations, XTL Biopharmaceuticals
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: <FONT STYLE="color: Blue"><U>ir@xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Blue"><U>www.xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Arrowhead Business and Investment Decisions,
LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">140 Broadway, 46th Floor, New York, NY
10005</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Daniel Renaud or Thomas Renaud</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1 212 619 6889</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">enquire@arrowheadbid.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Blue"><U>www.abid.co/NASDAQ.XTLB</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Cautionary Statement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain forward-looking
statements, about XTL&rsquo;s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as &quot;believe,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;may,&quot;
&quot;should&quot; or &quot;anticipate&quot; or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of XTL&rsquo;s authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
XTL&rsquo;s actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Many factors could cause XTL&rsquo;s actual activities or results to differ materially from the activities and results anticipated
in such forward-looking statements, including, but not limited to, the factors summarized in XTL&rsquo;s filings with the SEC and
in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile
and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation to publicly update
these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors
associated with an investment in our ADSs or ordinary shares, which are included in our Annual Report on Form 20-F as filed with
the U.S. Securities and Exchange Commission on April 28 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">XTL Biopharmaceuticals Ltd.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; font: 10pt Times New Roman, Times, Serif; text-align: center">5 Hacharoshet Street, Raanana, 43656, Israel</TD>
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: right">Page 2</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tel: +972 9 955 7080; email: <FONT STYLE="color: Blue"><U>ir@xtlbio.com</U></FONT></P>



<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
                                                                                                                             <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">XTL BIOPHARMACEUTICALS LTD.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">Date:
    August 26, 2015</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid; width: 46%"><FONT STYLE="font-size: 10pt">/s/
    Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !- /\# 2(  A$! Q$!_\0
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/*V2(?**FHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
